Savient Pharmaceuticals (SVNT) Posts Q4 Loss of 44c/Sh., Misses Views

Savient Pharmaceuticals (NASDAQ: SVNT) reported Q4 EPS of ($0.44), $0.06 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $3.71 million versus the consensus estimate of $3.51 million.

For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%